This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OCUP Ocuphire Pharma (OCUP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Ocuphire Pharma Stock (NASDAQ:OCUP) 30 days 90 days 365 days Advanced Chart Get Ocuphire Pharma alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.17▼$1.4652-Week Range N/AVolume676,700 shsAverage Volume171,840 shsMarket Capitalization$30.33 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company Overview Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan. Read More Receive OCUP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocuphire Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OCUP Stock News HeadlinesNight Vision Disturbances Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, ViatrisApril 10, 2025 | theglobeandmail.comShareholder group nominates slate of director candidates for Opus GeneticsFebruary 7, 2025 | markets.businessinsider.comRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns just aren’t enough anymore. But what if you could reach your Freedom Number—the monthly income that makes retirement secure—using far less money than you thought possible? That’s exactly what Kelly G. discovered. She calls it “life-changing,” saying the income just keeps growing and that early retirement suddenly looks real. This strategy was once reserved for the ultra-wealthy, but it’s now available to everyday investors. | Investors Alley (Ad)Opus Genetics sets April 30 for 2025 Annual MeetingJanuary 24, 2025 | msn.comOpus Genetics reinstated with a Buy at H.C. WainwrightNovember 14, 2024 | markets.businessinsider.comOpus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate UpdateNovember 12, 2024 | markets.businessinsider.comFoundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus GeneticsOctober 26, 2024 | finanznachrichten.deOcuphire Pharma, Inc. Announces Acquisition of Opus GeneticsOctober 26, 2024 | finanznachrichten.deSee More Headlines OCUP Stock Analysis - Frequently Asked Questions How were Ocuphire Pharma's earnings last quarter? Ocuphire Pharma, Inc. (NASDAQ:OCUP) announced its earnings results on Friday, August, 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.01. The firm earned $3.67 million during the quarter. Ocuphire Pharma had a negative trailing twelve-month return on equity of 30.19% and a negative net margin of 85.75%. What other stocks do shareholders of Ocuphire Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocuphire Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), ServiceNow (NOW), Novo Nordisk A/S (NVO) and e.l.f. Beauty (ELF). Company Calendar Last Earnings8/11/2023Today9/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:OCUP CIK1228627 Webwww.ocuphire.com Phone(248) 681-9815Fax240-268-5310Employees14Year FoundedN/APrice Target and Rating Average Price Target for Ocuphire Pharma$10.00 High Price Target$10.00 Low Price Target$10.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$9.99 million Net Margins-85.75% Pretax Margin-85.68% Return on Equity-30.19% Return on Assets-27.55% Debt Debt-to-Equity RatioN/A Current Ratio10.68 Quick Ratio10.68 Sales & Book Value Annual Sales$16.45 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.20 per share Price / BookN/AMiscellaneous Outstanding Shares25,924,000Free Float24,469,000Market Cap$30.33 million OptionableOptionable Beta0.20 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:OCUP) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocuphire Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocuphire Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCUP Stock Alerts